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background
 
Very high plasma homocysteine levels are characteristic of homocystinuria, a rare auto-
somal recessive disease accompanied by the early onset of generalized osteoporosis.
We therefore hypothesized that mildly elevated homocysteine levels might be related to
age-related osteoporotic fractures.
 
methods
 
We studied the association between circulating homocysteine levels and the risk of in-
cident osteoporotic fracture in 2406 subjects, 55 years of age or older, who partici-
pated in two separate prospective, population-based studies. In the Rotterdam Study,
there were two independent cohorts: 562 subjects in cohort 1, with a mean follow-up
period of 8.1 years; and 553 subjects in cohort 2, with a mean follow-up period of 5.7
years. In the Longitudinal Aging Study Amsterdam, there was a single cohort of 1291
subjects, with a mean follow-up period of 2.7 years. Multivariate Cox proportional-
hazards regression models were used for analysis of the risk of fracture, with adjust-
ment for age, sex, body-mass index, and other characteristics that may be associated
with the risk of fracture or with increased homocysteine levels.
 
results
 
During 11,253 person-years of follow-up, osteoporotic fractures occurred in 191 sub-
jects. The overall multivariable-adjusted relative risk of fracture was 1.4 (95 percent con-
fidence interval, 1.2 to 1.6) for each increase of 1 SD in the natural-log–transformed
homocysteine level. The risk was similar in all three cohorts studied, and it was also
similar in men and women. A homocysteine level in the highest age-specific quartile
was associated with an increase by a factor of 1.9 in the risk of fracture (95 percent con-
fidence interval, 1.4 to 2.6). The associations between homocysteine levels and the risk
of fracture appeared to be independent of bone mineral density and other potential risk
factors for fracture.
 
conclusions
 
An increased homocysteine level appears to be a strong and independent risk factor for
osteoporotic fractures in older men and women.
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steoporosis is a major health
 
problem that is characterized by low bone
mineral density, deterioration of bone mi-
croarchitecture, and an increased risk of fracture.
 
1
 
Osteoporotic fractures are associated with increased
morbidity and mortality and with substantial eco-
nomic costs.
 
2-4
 
It has been hypothesized that the metabolism of
homocysteine is involved in osteoporosis. Homo-
cystinuria, a rare autosomal recessive disease char-
acterized by markedly elevated levels of plasma
homocysteine, has several clinical manifestations
involving the eyes, the vasculature, and the central
nervous system. The presence of homocystinuria is
associated with the early onset of generalized os-
teoporosis.
 
5,6
 
 The underlying pathophysiological
mechanism for the occurrence of early osteoporo-
sis in patients who have homocystinuria is not com-
pletely understood. However, in vivo and in vitro
studies support the concept that a homocysteine-
associated disturbance in collagen cross-linking in
bone is involved.
 
7-11
 
In the general population, a mildly elevated plas-
ma level of homocysteine, termed hyperhomocys-
teinemia, is a common condition. Hyperhomocys-
teinemia is recognized as a major risk factor for
atherosclerotic and thromboembolic disease
 
12
 
 as
well as for cognitive impairment, including that
seen in Alzheimer’s disease.
 
13,14
 
 Although a previ-
ous study suggested the possible involvement of in-
creased plasma homocysteine levels in age-depen-
dent bone loss,
 
15
 
 the role of moderately elevated
plasma homocysteine levels in diseases of the skele-
tal system — in particular, osteoporotic fracture —
is unknown. To examine the influence of homocys-
teine on osteoporosis, we studied the relationship
between circulating levels of homocysteine and the
incidence of fracture in two independent, prospec-
tive studies of three groups of men and women 55
years of age or older.
 
study subjects
 
We analyzed data from two independent samples,
one sample from the Rotterdam Study consisting of
two cohorts of subjects, and the other sample from
the Longitudinal Aging Study Amsterdam (LASA).
The Rotterdam Study is a prospective, ongoing
population-based, cohort study of persons 55 years
of age or older residing in the Ommoord district of
the city of Rotterdam, in the Netherlands. The study
was designed to investigate chronic, disabling dis-
eases. The rationale and design of the study have
been described previously.
 
16
 
 The baseline examina-
tion included 7983 subjects. The medical ethics
committee of the Erasmus Medical Center approved
the Rotterdam Study.
Two independent, nonoverlapping samples of
subjects were included in the present study. At base-
line (1991–1993), a random sample of 562 subjects
was studied (cohort 1), and at a follow-up visit
(1995–1996), a second sample of 553 subjects was
studied (cohort 2). Cohort 2 was originally recruited
for a study of age-related changes in the brains of
elderly persons,
 
17
 
 and the exclusion criteria were
dementia, blindness, and the presence of standard
contraindications to the use of magnetic resonance
imaging. The subjects in cohort 2 ranged in age
from 60 to 90 years and were randomly selected,
with stratification according to age (in five-year
groups) and sex.
LASA is an ongoing cohort study of the predic-
tors and consequences of changes in autonomy and
well-being in older persons in the Netherlands. The
procedures used in sampling and data collection
have been described in detail elsewhere.
 
18
 
 Briefly, a
sample of persons 55 to 85 years of age, stratified
according to age, sex, and level of urbanization of
residence (number of addresses per square kilo-
meter), was drawn from the population registers of
11 municipalities. At the baseline examination (in
1992 or 1993), 3107 subjects participated. The pres-
ent study was performed with a subsample of 1291
persons who were interviewed at the time of the
second collection of data (in 1995 or 1996) and who
were 65 years of age or older on January 1, 1996.
The medical ethics committee of the Vrije Univer-
siteit Medical Center approved the study.
All the subjects in the Rotterdam Study and
LASA who participated in the present study gave
written informed consent.
 
assessment of fractures
 
In the Rotterdam Study, general practitioners mon-
itored the subjects for incident fractures, which were
reported by means of a computerized system. Events
were classified independently by two research phy-
sicians according to the 
 
International Statistical Classi-
fication of Diseases and Related Health Problems, 10th
Revision
 
 (ICD-10-CM).
 
19
 
 An expert in osteoporosis
reviewed all coded events for final classification.
For this study, follow-up ended on January 1, 2002.
In LASA, fractures that occurred between the
methods
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second examination (in 1995 or 1996) and the third
examination (in 1998 or 1999) were recorded pro-
spectively on a calendar. Information about frac-
tures was noted retrospectively for respondents who
did not participate in the follow-up. All reported
fractures were verified by a physician.
To ensure sufficient statistical power, a fracture
in any skeletal location was documented as an out-
come measure. All fractures that were considered
to be nonosteoporotic (i.e., fractures due to cancer
or to an accident, such as a motor vehicle accident,
and all hand, foot, skull, and facial fractures) were
excluded. The period of follow-up was calculated as
the time from enrollment in the study to the first
fracture, death, or the end of the planned follow-up
period, whichever occurred first. For subjects lost
to the study during follow-up, the follow-up period
was calculated as the time from enrollment to the
date of the last contact with the subject.
 
measurement of bone mineral density
 
Bone mineral density was measured by dual-energy
x-ray absorptiometry at the femoral neck and lum-
bar spine (vertebrae L2–L4 in the Rotterdam Study
and L1–L4 in LASA).
 
20,21
 
 In the Rotterdam Study,
bone mineral density was measured with the use of
a Lunar DPX-L densitometer (Lunar), and in LASA,
measurements were made with the use of a Hologic
QDR 2000 densitometer (Hologic).
 
measurement of homocysteine levels
 
Blood samples were placed on ice immediately, pro-
cessed within 60 minutes, and kept frozen until ho-
mocysteine levels were measured. For cohort 1 of
the Rotterdam Study, serum samples were obtained
from subjects who were not fasting, and total ho-
mocysteine levels were determined as a fluorescence
derivative with the use of high-pressure liquid chro-
matography.
 
22,23
 
 For cohort 2 of the Rotterdam
Study, plasma samples treated with sodium citrate
were obtained from subjects who were not fasting,
whereas in the LASA group, EDTA-treated plasma
samples were obtained in the morning, after sub-
jects had eaten a light breakfast. Total homocysteine
levels were measured with the use of a fluorescence
polarization immunoassay on an IMx analyzer (Ab-
bott Laboratories).
 
potential confounders
 
Height and weight were measured while the study
subjects were wearing lightweight clothing and no
shoes. Data on the body-mass index before the pres-
ent study were available for cohort 2 of the Rotter-
dam Study (over a period of approximately 2.4 years)
and for subjects in LASA (over a period of approxi-
mately 3.0 years), and we calculated the change in
the body-mass index between the most recent pre-
vious visit and enrollment in the present study. Cur-
rent smoking status and the number of falls in the
preceding year were assessed with the use of a
questionnaire.
Levels of serum creatinine were measured with
the use of standard laboratory procedures. In the
Rotterdam Study, the presence of type 2 diabetes
mellitus was defined by the current use of antidia-
betic medication or by a nonfasting or post-load
plasma glucose level above 11 mmol per liter. Pe-
ripheral arterial disease was evaluated as described
previously.
 
24
 
In cohort 1 of the Rotterdam Study, dementia was
diagnosed with the use of the Mini–Mental State Ex-
amination and the Geriatric Mental State Sched-
ule,
 
25
 
 and dietary intake of calories, protein, calci-
um, 25-hydroxyvitamin D, folate, and vitamins B
 
6
 
and B
 
12
 
 during the preceding year was assessed with
the use of a food-frequency questionnaire.
 
26
 
 In
LASA, the presence of diabetes and peripheral arte-
rial disease was assessed with the use of a detailed
questionnaire concerning self-reported chronic dis-
ease.
 
27
 
 Cognitive impairment was diagnosed with
the use of the Mini–Mental State Examination; a
score below 24 was considered to be positive for
cognitive impairment. Levels of serum 25-hydroxy-
vitamin D were measured with the use of a compet-
itive protein-binding assay (Nichols Institute Diag-
nostics).
 
statistical analysis
 
The distribution of the plasma homocysteine levels
was skewed toward higher values. Therefore, we
used natural-log–transformed values, which provid-
ed the best-fitting model for analyses in which the
plasma homocysteine levels were treated as a con-
tinuous variable. In order to compare the homocys-
teine levels in the three cohorts with one another,
sex-specific standard-deviation scores were cal-
culated separately for each subject in each cohort.
The standard-deviation score was calculated with
the formula (hcys
 
i
 
¡hcys
 
m
 
)÷SD, where hcys
 
i
 
 is the
natural-log–transformed homocysteine level in
the individual subject, hcys
 
m
 
 the mean natural-log–
transformed homocysteine level in the cohort, and
SD the standard deviation of the natural-log–trans-
formed homocysteine level in the cohort. This cal-
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culation allowed us to determine the increase in
the risk of fracture for each increment of 1 SD in the
natural-log–transformed homocysteine level.
The relation between the risk of fracture and
various homocysteine levels was evaluated with a
quartile-based analysis. The quartiles were defined
in a sex-specific and age-specific manner for each
of the five-year categories.
Cox proportional-hazards regression analysis
was used to estimate the risk of fracture. Data were
either pooled or were analyzed for each study sam-
ple. When all subjects were included, the analysis
was adjusted for the study cohort. All estimated risks
of fracture were adjusted for age and sex. Additional
analyses were adjusted for body-mass index, smok-
ing status, presence or absence of a history of re-
cent falls, and serum creatinine levels. In further
analyses, we also adjusted for recent changes in the
body-mass index and for dietary intake of calories,
protein, calcium, 25-hydroxyvitamin D, folate, and
vitamins B
 
6
 
 and B
 
12
 
 (or for serum 25-hydroxyvita-
min D), and the presence or absence of diabetes
mellitus, dementia (or cognitive impairment), and
peripheral arterial disease.
Population attributable risks were calculated
with the use of the formula {P(RR¡1)÷[P(RR¡1)
+1]}¬100, where P is the percentage of the popula-
tion exposed and RR is the relative risk. We calcu-
lated the 95 percent confidence interval by deter-
mining the 95 percent confidence interval for log
(P[RR¡1]) on the basis of the standard errors for
P and RR, with the use of the delta method, and
transforming back to the 95 percent confidence in-
terval for the population attributable risk.
 
baseline characteristics
 
Selected baseline characteristics of the study sub-
jects in the three cohorts are shown in Table 1. The
three cohorts differed significantly with regard to
mean age and sex ratio. Mean homocysteine levels
were different in all three cohorts; the levels in-
creased with age and were higher in men than in
women in all three cohorts (see the Supplementary
Appendix, available with the full text of this article
at www.nejm.org).
 
homocysteine levels and fracture risk
 
During 11,253 person-years of follow-up, 191 sub-
jects (135 women and 56 men) sustained an os-
teoporotic fracture; a majority were hip and wrist
fractures (Table 2). High homocysteine levels were
associated with an increased risk of fracture (Ta-
ble 3). After adjustment for age and sex, the overall
relative risk of fracture for each increment of 1 SD
in the homocysteine level was 1.3 when all sub-
jects were pooled. The risk of fracture with increas-
ing homocysteine levels was similar in all three
groups of subjects (data not shown). The risk was
similar in men and women: 1.4 (95 percent confi-
dence interval, 1.1 to 2.8) in men, and 1.3 (95 per-
cent confidence interval, 1.1 to 1.5) in women.
Because the three cohorts differed with regard to
age and sex distribution (Table 1), the subjects were
grouped in sex- and age-specific quartiles according
results
 
* Plus–minus values are means ±SD. LASA denotes the Longitudinal Aging 
Study Amsterdam, and NA not available.
† The body-mass index is the weight in kilograms divided by the square of the 
height in meters.
‡ In the Rotterdam Study, homocysteine levels were determined in serum with 
the use of high-performance liquid chromatography for cohort 1 and in sodi-
um citrate–treated plasma with the use of an immunoassay for cohort 2. In 
LASA, homocysteine levels were determined in EDTA-treated plasma with the 
use of an immunoassay.
§ To convert the values for creatinine to milligrams per deciliter, divide by 88.4.
¶Measurements of bone mineral density were available for 474 subjects in co-
hort 1 of the Rotterdam Study, 475 subjects in cohort 2, and 515 subjects in 
LASA. The measurements used for subjects in cohort 2 of the Rotterdam 
Study had been obtained approximately 2.4 years before the study began. In 
the Rotterdam Study bone mineral density was measured with the use of a Lu-
nar densitometer, and in LASA with the use of a Hologic densitometer. Bone 
mineral density was measured at the lumbar spine in vertebrae L1–L4 in the 
 
Rotterdam Study and in vertebrae L2–L4 in LASA.
 
Table 1. Baseline Characteristics of Study Subjects.*
Characteristic Rotterdam Study
LASA
(N=1291)
 
Cohort 1
(N=562)
Cohort 2
(N=553)
Women — no. (%) 351 (62) 278 (50) 663 (51)
Age — yr 70.3±8.8 73.6±7.9 75.6±6.6
Body-mass index† 26.5±3.9 26.3±3.6 26.8±4.2
Current smoker — % 24 21 18
Fall in previous year — % 21 NA 32
Homocysteine level — µmol/liter‡ 15.9±5.7 11.9±4.3 14.7±6.0
Serum creatinine level — µmol/liter§ 82.6±20.4 89.1±20.2 93.6±22.0
Bone mineral density — g/cm
 
2
 
¶
Lumbar spine 1.09±0.20 1.11±0.21 0.97±0.19
Femoral neck 0.85±0.13 0.83±0.15 0.70±0.13
Follow-up — yr 8.1±3.7 5.7±1.9 2.7±0.7
Loss to follow-up — % 2.3 3.8 4.3
Incidence of fracture — no./1000 person-yr 18.2 15.8 16.4
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to the homocysteine level. In all three cohorts, sub-
jects in the highest quartile had an increase in the
risk of fracture so that the risk was twice as high as
the risk in each of the lower three quartiles. We sub-
sequently analyzed the homocysteine levels divided
into the highest quartile (risk group) and the lower
three quartiles combined (reference group) (Ta-
ble 3). The absolute cutoff values used to define the
risk groups are described in the Supplementary Ap-
pendix. Subjects in whom homocysteine levels were
above the cutoff value had a risk of fracture that was
two times as high as that for subjects with lower
values. The risk estimates were similar in all three
cohorts. The frequency of nontraumatic vertebral
fracture was doubled in the highest quartile (risk
group) (Table 2), although this trend did not reach
statistical significance (P=0.26). Figure 1 shows the
cumulative incidence of fracture in the three cohorts
according to the age-specific quartile of homocys-
teine levels.
 
* Extremities include the arm, leg, and ankle.
 
Table 2. Distribution of Types of Incident Fracture According to Study Cohort and the Quartile of Homocysteine Level.
Type of Fracture Rotterdam Study LASA Total Homocysteine Level
 
Cohort 1 Cohort 2 Quartiles 1–3 Quartile 4
 
number (percent)
 
Hip 22 (27) 11 (22) 18 (31) 51 (27) 36 (29) 15 (23)
Wrist 21 (25) 14 (28) 18 (31) 53 (28) 37 (29) 16 (25)
Upper humerus 10 (12) 3 (6) 8 (14) 21 (11) 15 (12) 6 (9)
Vertebrae 7 (8) 7 (14) 2 (3) 16 (8) 8 (6) 8 (12)
Extremities* 19 (23) 10 (20) 8 (14) 37 (19) 25 (20) 12 (18)
Rib and sternum 3 (4) 3 (6) 3 (5) 9 (5) 3 (2) 6 (9)
Pelvis 1 (1) 2 (4) 1 (2) 4 (2) 2 (2) 2 (3)
Total 83 (100) 50 (100) 58 (100) 191 (100) 126 (100) 65 (100)
 
* Homocysteine levels were analyzed as a continuous measure. The relative risk (RR) is for each increment of 1 SD in the 
natural-log–transformed homocysteine value. CI denotes confidence interval.
† The homocysteine level was analyzed as a dichotomous variable. The relative risk is for subjects in the highest quartile of 
homocysteine levels, as compared with subjects in the three lower quartiles.
‡ This analysis included adjustments for age, sex, body-mass index, changes in body-mass index before entry into the 
study, smoking status, presence or absence of a history of recent falls, and serum creatinine level. Data for changes in 
previous body-mass index were not available for cohort 1 of the Rotterdam Study, and data for recent falls were not avail-
able for cohort 2.
§ This analysis included adjustments for age, sex, body-mass index, smoking status, and presence or absence of a history 
of recent falls, diabetes mellitus, dementia (in the Rotterdam Study) or cognitive impairment (in LASA), peripheral arte-
 
rial disease, and serum creatinine level.
 
Table 3. Results of Multivariate Analyses of the Relationship between Homocysteine Levels and the Risk of Fracture 
in the Three Study Cohorts.
Analysis Continuous Analysis* Quartile-Specific Analysis†
 
No. of Fractures/
No. of Subjects RR (95% CI)
No. of Fractures/
No. of Subjects RR (95% CI)
Adjusted for age and sex 191/2406 1.3 (1.1–1.5) 191/2406 1.9 (1.4–2.6)
Multivariate 1‡ 180/2332 1.4 (1.2–1.6) 180/2332 2.0 (1.4–2.8)
Multivariate 2§ 180/2332 1.4 (1.2–1.6) 180/2332 2.0 (1.4–2.7)
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homocysteine levels 
and bone mineral density
 
As shown in Figure 2, after adjustment for age and
sex, homocysteine levels were not associated with
bone mineral density at either the femoral neck or
the lumbar spine. When we included bone mineral
density in the multivariate regression model, the risk
estimates were not substantially changed.
 
possible confounding variables
 
The association between homocysteine levels and
the risk of fracture was not reduced after adjustment
for the body-mass index, changes in the body-mass
index, smoking status, recent falls, serum creatinine
levels, and the presence or absence of diabetes mel-
litus, peripheral arterial disease, and dementia or
cognitive impairment (Table 3). In addition, the ob-
served association between homocysteine levels and
the risk of fracture in cohort 1 of the Rotterdam
Study was not substantially reduced after adjust-
ment for dietary intake of calories, protein, calcium,
and vitamins (data not shown). The same analysis
could not be performed for cohort 2 of the Rotter-
dam Study or for LASA, because data on dietary in-
take were not available for those cohorts. Instead,
serum levels of 25-hydroxyvitamin D were used as
a measure of nutritional status for subjects in LASA,
and adjustment for this covariable did not alter the
risk estimates.
 
population attributable risk
 
Table 4 shows the population attributable risks for
the independent risk factors for fracture in the total
study population. The risk of fracture that was at-
tributable to a homocysteine level in the highest age-
specific quartile was estimated at 19 percent. The
association of a high homocysteine level with the oc-
currence of incident fractures was similar to the as-
sociation of the risk of fracture with low bone min-
eral density, cognitive impairment, and recent falls.
Our analyses of data from three cohorts of subjects
in two independent studies show a strong associa-
discussion
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Figure 1. Cumulative Incidence of Fracture among Study 
Subjects with Homocysteine Levels in the Highest Age- 
and Sex-Specific Quartile as Compared with All Other 
Subjects.
 
RR denotes relative risk, and CI confidence interval.
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tion between increased homocysteine levels and
the risk of osteoporotic fracture. The age- and sex-
adjusted risk of fracture increased by 30 percent
for each increase of 1 SD in the homocysteine level.
A serum homocysteine level in the highest quartile
doubled the risk of fracture. The magnitude of this
effect is similar to that previously observed for the
increase in the risk of cardiovascular disease and
dementia according to homocysteine level.
 
12-14,28
 
A novel aspect of this study is an examination of
the relationship between the risk of fracture and
homocysteine levels in a general, older population.
The association appears to be consistent within this
population, since we found similar risk estimates in
the two cohorts of the Rotterdam Study and in LASA.
The association appears to be independent of age,
sex, and other risk factors for fracture, such as
smoking, recent falls, dementia, diabetes mellitus,
peripheral arterial disease, and nutritional deficien-
cy. In view of the inherent limitation of measuring
dietary intake by means of a questionnaire, nutri-
tional deficiency cannot be completely ruled out as
a confounder.
The calculated population attributable risk of
the effects of increased homocysteine levels is con-
siderable. A homocysteine level in the highest age-
specific quartile conferred a 19 percent attributable
risk in our population. The population attributable
risks were similar for well-known risk factors for
fracture, such as low bone mineral density, cogni-
tive impairment, and recent falls, in the study pop-
ulation. A recent report showed that in the Rotter-
dam Study, the population attributable risks of
myocardial infarction associated with hypercholes-
terolemia and hypertension — two well-known risk
factors — were 18 percent and 14 percent, respec-
tively.
 
29
 
 Thus, a high homocysteine level appears to
have an effect whose size is similar to that of estab-
lished risk factors for fractures and for cardiovas-
cular disease.
There were considerable differences in the tech-
niques used to assess homocysteine levels in the
three study cohorts. For cohort 1 of the Rotterdam
Study, serum samples were obtained, and for co-
hort 2, sodium citrate–treated plasma samples were
obtained. In LASA, EDTA plasma samples were
used. Furthermore, different methods were used to
 
Figure 2. Mean (±SD) Bone Mineral Density (BMD) According to Age- and Sex-Specific Quartile of Homocysteine Levels.
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* All relative risks were adjusted for age and sex, except for an age of more than 
75 years. CI denotes confidence interval, and BMD bone mineral density.
† Only data from cohort 1 of the Rotterdam Study and LASA were used to calcu-
 
late the population attributable risk.
 
Table 4. Relative Risks and Population Attributable Risks for Independent 
Risk Factors for Incident Fracture.*
Factor
Relative Risk
(95% CI)
Population Attributable
Risk (95% CI)
 
%
 
Age >75 yr 2.3 (1.7–3.1) 31 (25–48)
BMD, lowest quartile 1.6 (1.1–2.3) 13 (2–25)
Current smoker 1.6 (1.1–2.3) 10 (4–23)
Fall in previous year† 1.9 (1.2–2.7) 20 (10–35)
Dementia and cognitive impairment† 2.5 (1.5–4.1) 15 (7–30)
Homocysteine level, highest quartile 1.9 (1.4–2.6) 19 (10–29)
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determine the homocysteine levels. These differ-
ences in method are known to influence the mea-
surement of homocysteine levels.
 
30-32
 
 Together with
differences in the age and sex distribution among
the three cohorts, the differences in method may ex-
plain the considerable variation in the mean homo-
cysteine levels among the three cohorts. Despite
these differences, an association between the homo-
cysteine level and the risk of fracture was consistent
in each cohort. Thus, this association appears to be
independent of the method of measuring homo-
cysteine levels. However, because of the large differ-
ences among the three cohorts, we refrained from
using a single cutoff value for the presence of hyper-
homocysteinemia.
According to a long-standing hypothesis, the
mechanism underlying the association between the
homocysteine level and the risk of fracture may in-
volve interference by homocysteine in collagen
cross-linking.
 
7
 
 Homocysteine has been shown to
interfere specifically with the formation of collagen
cross-links and fibrils in solution.
 
10
 
 In addition,
lower amounts of collagen cross-links have been
found in serum from patients who have homocys-
tinuria — that is, persons with very high levels of
circulating homocysteine — than in normal con-
trols.
 
11
 
 Because collagen cross-links are important
for the stability and strength of the collagen net-
work, interference in the formation of cross-links
results in an altered bone matrix, which then re-
sults in fragile bone. Thus, increased homocysteine
levels could lead to an increase in the risk of frac-
ture through interference in collagen cross-linking.
We therefore speculate that homocysteine interferes
with the development of the microarchitecture of
bone independently of the amount of mineral in the
bone. This notion was corroborated by the fact that
we did not find evidence of a relationship between
homocysteine levels and bone mineral density.
The association between elevated homocysteine
levels and the risk of fracture should be confirmed
in other large population studies. Proof of a causal
relationship between increased homocysteine levels
and bone disease could be established by interven-
tion studies aimed at lowering the serum homo-
cysteine level. Whereas randomized, controlled
trials have shown that folic acid–based vitamin
supplements can effectively reduce homocysteine
levels
 
33
 
 and reduce the rate of coronary resteno-
sis,
 
34
 
 additional studies are needed to assess wheth-
er the use of such therapy will reduce the risk of
fracture.
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